Catalent
CTLT
$56.02
Share price
0.39%
Change (1 day)
32.25%
Change (1 year)
Categories
Catalent is an American pharmaceutical contract research and development company.
Earnings for Catalent (CTLT)
Earnings in 2023 (TTM): -$1.21 B
According to Catalent's latest financial reports the company's current earnings (TTM) are -$1.21 B. In 2022 the company made an earning of $0.64 B a decrease over its 2021 earnings that were of $0.87 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Catalent from 2013 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | -$1.21 B | -286.27% |
| 2022 | $0.64 B | -25.81% |
| 2021 | $0.87 B | 77.66% |
| 2020 | $0.49 B | 62.46% |
| 2019 | $0.30 B | 10.64% |
| 2018 | $0.27 B | 18.66% |
| 2017 | $0.23 B | 9.14% |
| 2016 | $0.21 B | -15.11% |
| 2015 | $0.24 B | 15.35% |
| 2014 | $0.21 B | 10.45% |
| 2013 | $0.19 B |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | $5.18 M | -100.43% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | $0.29 B | -124.68% | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | -$23.25 M | -98.07% | 🇺🇸 USA |
 Intercept Pharmaceuticals
ICPT | -$58.01 M | -95.19% | 🇺🇸 USA |